日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Corrigendum to "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer": [ESMO Open 9 (2024) 103647]

对“泛亚洲版 ESMO 胆道癌患者诊断、治疗和随访临床实践指南”的更正：[ESMO Open 9 (2024) 103647]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.104074
Chen, L-T; Vogel, A; Hsu, C; Chen, M-H; Fang, W; Pangarsa, E A; Sharma, A; Ikeda, M; Park, J O; Tan, C K; Regala, E; Tai, D; Tanasanvimon, S; Charoentum, C; Chee, C E; Lui, A; Sow, J; Oh, D-Y; Ueno, M; Ramaswamy, A; Jeo, W S; Zhou, J; Curigliano, G; Yoshino, T; Bai, L-Y; Pentheroudakis, G; Chiang, N-J; Cervantes, A; Chen, J-S; Ducreux, M
SMO
肿瘤
胆管癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

泛亚洲版ESMO胆道癌诊断、治疗和随访临床实践指南

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103647
Chen, L-T; Vogel, A; Hsu, C; Chen, M-H; Fang, W; Pangarsa, E A; Sharma, A; Ikeda, M; Park, J O; Tan, C K; Regala, E; Tai, D; Tanasanvimon, S; Charoentum, C; Chee, C E; Lui, A; Sow, J; Oh, D-Y; Ueno, M; Ramaswamy, A; Jeo, W S; Zhou, J; Curigliano, G; Yoshino, T; Bai, L-Y; Pentheroudakis, G; Chiang, N-J; Cervantes, A; Chen, J-S; Ducreux, M
SMO
肿瘤
胆管癌
肿瘤免疫
发表日期：2024
文献求助 收藏

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

泛亚洲版ESMO临床实践指南：致癌基因依赖性转移性非小细胞肺癌患者的诊断、治疗和随访

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103996
Lee, S-H; Menis, J; Kim, T M; Kim, H R; Zhou, C; Kurniawati, S A; Prabhash, K; Hayashi, H; Lee, D D-W; Imasa, M S; Teh, Y L; Yang, J C-H; Reungwetwattana, T; Sriuranpong, V; Wu, C-E; Ang, Y; Sabando, M; Thiagarajan, M; Mizugaki, H; Noronha, V; Yulianti, M; Zhang, L; Smyth, E; Yoshino, T; Park, J O; Pentheroudakis, G; Park, S; Peters, S; Ahn, J B; Popat, S
肺癌
SMO
肿瘤
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)

脂质体伊立替康联合氟尿嘧啶/亚叶酸钙与 FOLFIRINOX 方案作为转移性胰腺癌患者二线化疗的比较：韩国癌症研究组 (KCSG) 的一项多中心回顾性研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100049
Park, H S; Kang, B; Chon, H J; Im, H-S; Lee, C-K; Kim, I; Kang, M J; Hwang, J E; Bae, W K; Cheon, J; Park, J O; Hong, J Y; Kang, J H; Kim, J H; Lim, S H; Kim, J W; Kim, J-W; Yoo, C; Choi, H J
胰腺癌
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

接受奥拉帕尼维持治疗的携带生殖系 BRCA 突变和转移性胰腺癌患者的健康相关生活质量

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz406
Hammel, P; Kindler, H L; Reni, M; Van Cutsem, E; Macarulla, T; Hall, M J; Park, J O; Hochhauser, D; Arnold, D; Oh, D-Y; Reinacher-Schick, A; Tortora, G; Algül, H; O'Reilly, E M; McGuinness, D; Cui, K Y; Joo, S; Yoo, H K; Patel, N; Golan, T
胰腺癌
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

基因组改变对拉帕替尼治疗结果和HER2阳性胃癌患者HER2治疗期间无细胞基因组图谱的影响

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdy034
Kim, S T; Banks, K C; Pectasides, E; Kim, S Y; Kim, K; Lanman, R B; Talasaz, A; An, J; Choi, M G; Lee, J H; Sohn, T S; Bae, J M; Kim, S; Park, S H; Park, J O; Park, Y S; Lim, H Y; Kim, N K D; Park, W; Lee, H; Bass, A J; Kim, K; Kang, W K; Lee, J
胃癌
肿瘤
肿瘤免疫
HER2
细胞生物学
发表日期：2018
文献求助 收藏

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

结直肠癌患者的 MAP2K1 突变：使用患者来源的肿瘤细胞系的治疗挑战

期刊:Journal of Cancer
影响因子:3.3
doi:10.7150/jca.19582
J E Kim, K K Kim, S Y Kim, J Lee, S H Park, J O Park, Y S Park, H Y Lim, W K Kang, S T Kim
肿瘤
肠癌
肿瘤细胞
发表日期：2017
文献求助 收藏

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

一项随机、双盲、安慰剂对照的多中心III期临床试验，研究XELIRI/FOLFIRI联合辛伐他汀治疗转移性结直肠癌患者的疗效

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2015.371
Lim, S H; Kim, T W; Hong, Y S; Han, S-W; Lee, K-H; Kang, H J; Hwang, I G; Lee, J Y; Kim, H S; Kim, S T; Lee, J; Park, J O; Park, S H; Park, Y S; Lim, H Y; Jung, S-H; Kang, W K
肿瘤
肠癌
肿瘤免疫
发表日期：2015
文献求助 收藏

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

一项随机II期临床试验，评估多西他赛联合舒尼替尼治疗既往接受过氟尿嘧啶和铂类药物治疗的转移性胃癌患者的疗效。

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2012.100
Yi, J H; Lee, J; Lee, J; Park, S H; Park, J O; Yim, D-S; Park, Y S; Lim, H Y; Kang, W K
胃癌
肿瘤
肿瘤免疫
发表日期：2012
文献求助 收藏

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

LKB1 肿瘤抑制基因的突变在白种人肺癌患者的肿瘤中经常被检测到，但在亚洲肺癌患者的肿瘤中则很少被检测到

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6604469
Koivunen J P, Kim J, Lee J, Rogers A M, Park J O, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap B Y, Meyerson M, Wong K-K, Richards W G, Sugarbaker D J, Johnson B E, Jänne P A
肿瘤
肺癌
发表日期：2008
文献求助 收藏